Answers are grounded in this paper and cite their sources.
MOBILITY is the largest prospective study to date to provide QoL data over a variety of therapeutic indications following treatment with onabotulinumtoxinA. Although the QoL burden varies by disease, data suggest that long-term treatment may help improve or maintain QoL over time.
No takes yet. Share an insight, caveat, or question.
Jog et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: